Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas.
The goal of multimodality therapy for localized pancreatic cancer is to maximize local-regional disease control and patient survival. In contrast to surgery for other solid tumors, prolonged recovery following pancreaticoduodenectomy may prevent the timely delivery of postoperative adjuvant therapy. Therefore, efforts at The University of Texas, M.D. Anderson Cancer Center have focused on the delivery of chemotherapy and radiation therapy prior to surgery in patients with localized pancreatic cancer. Clinical trials have emphasized the use of altered-fractionation schedules of radiation therapy combined with novel radiation-sensitizing agents. All treatment schemes aim to decrease toxicity and treatment time while improving therapeutic efficacy.
Department of Surgical Oncology, University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.
A R
AR
Miller
P W
PW
Pisters
J E
JE
Lee
N A
NA
Janjan
J L
JL
Abbruzzese
D B
DB
Evans
D000230:Adenocarcinoma / Q000401:mortality / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D006801:Humans; D009389:Neovascularization, Pathologic / Q000517:prevention & control; D017239:Paclitaxel / Q000627:therapeutic use; D010190:Pancreatic Neoplasms / Q000401:mortality / Q000628:therapy*; D016577:Pancreaticoduodenectomy; D011300:Preoperative Care; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use; D018714:Radiotherapy, Adjuvant; D016896:Treatment Outcome
D011838:Radiation-Sensitizing Agents; D017239:Paclitaxel